INDP
NASDAQ · Biotechnology
Indaptus Therapeutics Inc
$3.06
-0.35 (-10.26%)
Open$3.41
Previous Close$3.41
Day High$3.59
Day Low$2.81
52W High$13.44
52W Low$0.92
Volume—
Avg Volume707.7K
Market Cap386.16M
P/E Ratio—
EPS$-16.83
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+1,232.4% upside
Current
$3.06
$3.06
Target
$40.77
$40.77
$30.54
$40.77 avg
$54.50
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 1.71M | 1.62M | 1.61M |
| Net Income | -161,760 | -172,924 | -142,728 |
| Profit Margin | -9.5% | -10.7% | -8.9% |
| EBITDA | -256,082 | -275,942 | -257,647 |
| Free Cash Flow | -132,527 | -99,336 | -105,630 |
| Rev Growth | +0.4% | +1.6% | -5.5% |
| Debt/Equity | 0.26 | 0.25 | 0.24 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $254.31 | +0.38% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $360.55 | +0.62% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.33 | -1.21% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $499.65 | +1.69% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $631.81 | -0.17% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $293.52 | +0.74% | 69.3 | 39.97B |